Effects of a bifid triple viable capsule on inflammatory factors and intestinal barrier function in children with...

Area of Science:

• Pediatric Gastroenterology
• Microbiology
• Immunology

Background:

• Abdominal infections in children present significant challenges due to inflammation and compromised intestinal barrier function.
• Current treatments aim to manage symptoms and restore gut health, but novel therapeutic approaches are continuously sought.

Purpose of the Study:

• To evaluate the efficacy of Bifid Triple Viable (BTV) capsules in managing inflammatory markers and enhancing intestinal barrier function in pediatric abdominal infections.

Main Methods:

• A randomized controlled trial involving 100 children with abdominal infections was conducted.
• The observation group received BTV capsules alongside conventional treatment, while the control group received conventional treatment alone.
• Key outcomes measured included clinical symptom remission, inflammatory cytokine levels, intestinal barrier integrity markers, gut microbiota composition, and immune function indices.

Main Results:

• Children treated with BTV capsules showed significantly faster remission of vomiting, fever, diarrhea, and abdominal pain.
• BTV treatment led to reduced levels of pro-inflammatory cytokines (IL-6, CRP, TNF-α) and increased IFN-γ.
• Improvements in intestinal barrier function were evidenced by lower levels of DAO, D-lactic acid, and LPS, and increased expression of Occludin and ZO-1.

Conclusions:

• Bifid Triple Viable (BTV) capsules demonstrate a therapeutic benefit in pediatric abdominal infections.
• BTV treatment effectively modulates the inflammatory response and strengthens the intestinal mucosal barrier.
• The findings suggest BTV is a promising adjunctive therapy for improving gut health and immune function in children with abdominal infections.